EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia

Andrew S Haynes, Holly Maples, Sarah Parker

Journal of the Pediatric Infectious Diseases Society · 2023

DOI: 10.1093/jpids/piad032 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of the Pediatric Infectious Diseases Society, 2023. Verfasst von Andrew S Haynes und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Section of Pediatric Infectious Diseases, Children's Hospital Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Methicillin-Resistant Staphylococcus aureus, Staphylococcal Infections, Bacteremia. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 112 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vancomycin remains the standard of care for treating methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in pediatrics largely because no alternative antibiotic is definitively superior. Long-standing historical precedent and S. aureus’ notable lack of vancomycin resistance are clear benefits, but vancomycin’s use remains plagued by nephrotoxicity and the need for therapeutic drug monitoring, with inadequate consensus on how best to dose or monitor vancomycin in pediatrics. Daptomycin, ceftaroline, and linezolid are all promising alternatives, with improved safety relative to vancomycin. However, inadequate and variable efficacy data limit confidence in their use. Despite this, we contend that it is time for clinicians to reconsider vancomycin’s place in clinical use. In this review, we summarize the supporting data for using vancomycin versus these other anti-MRSA antibiotics, present a framework for antibiotic decision-making that considers patient-specific factors, and discuss approaches to antibiotic selection for various etiologies of MRSA bacteremia. This review aims to help pediatric clinicians choose among the various treatment options for MRSA bacteremia, acknowledging that the optimal antibiotic choice is sometimes uncertain.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Methicillin-Resistant Staphylococcus aureusStaphylococcal InfectionsBacteremiaHumansChildVancomycinStaphylococcus aureusAnti-Bacterial Agents

Stichwörter der Autor:innen

MRSA bacteremiaceftarolinedaptomycinlinezolidpediatricsvancomycin

Substanzen

VancomycinAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Pediatrics, Section of Pediatric Infectious Diseases, Children's Hospital Colorado, Aurora, Colorado, USA.
  • University of Colorado School of Medicine, Aurora, Colorado, USA.
  • University of Arkansas for Medical Sciences College of Pharmacy, Little Rock, Arkansas, USA.
  • Arkansas Children's, Quality and Safety Division, Little Rock, Arkansas, USA.

Zitieren

APA

Haynes, A. S., Maples, H., & Parker, S. (2023). Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of the Pediatric Infectious Diseases Society. https://doi.org/10.1093/jpids/piad032

Vancouver

Haynes AS, Maples H, Parker S. Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia. Journal of the Pediatric Infectious Diseases Society. 2023. doi:10.1093/jpids/piad032

BibTeX
@article{Haynes2023,
  author = {Haynes, Andrew S and Maples, Holly and Parker, Sarah},
  title = {Time for a Change: Considering Vancomycin Alternatives for Pediatric Methicillin-Resistant Staphylococcus aureus Bacteremia},
  journal = {Journal of the Pediatric Infectious Diseases Society},
  year = {2023},
  doi = {10.1093/jpids/piad032}
}
Kostenlos starten →